Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

dMed, a Shanghai Clinical CRO, Opens Washington Office for US FDA Filings

publication date: Jun 20, 2019

dMed Biopharma, a Shanghai clinical CRO, has opened a Washington office to help China biopharmas complete their US regulatory filings. Since 2017, China's harmonization with the regulatory systems of other countries revolutionized the opportunities for China biopharmas, the company said. The number of US INDs filed by China biopharmas jumped from 11 in 2016 to 38 in 2018, a number that was equaled in the first quarter of 2019 alone. Among other things, the dramatic rise reflects the effect of numerous China-developed CAR-T candidates. dMed's Washington office is led by Dr. Eric Zhang, a former FDA reviewer. More details....

Share this with colleagues:

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China